Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenvatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.94 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 0.94 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.94 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.94 |
| ▸ | RET | P07949 | 6/20 | 0.94 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.94 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.94 |
| ▸ | KIT | P10721 | 3/20 | 0.94 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.94 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.94 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.94 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.94 |
| ▸ | STK10 | O94804 | 2/20 | 0.94 |
| ▸ | ABL1 | P00519 | 2/20 | 0.94 |
| ▸ | BCR | P11274 | 2/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.94 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.94 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.94 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenvatinib SCHEMBL29357626 | 1.00 | FGFR4 (0.94) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL29368684 | 1.00 | FGFR4 (0.94) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL3928020 | 0.97 | FGFR4 (0.91) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL864638 | 0.97 | FGFR4 (1.00) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL29349806 | 0.97 | FGFR4 (1.00) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL29372021 | 0.97 | FGFR4 (1.00) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL1389214 | 0.96 | FGFR4 (0.98) | FGFR4RETKDRFGFR1PDGFRB | |
| SCHEMBL28586143 | 0.92 | FGFR4 (0.91) | FGFR4RETKDRFGFR1PDGFRB | |
| SCHEMBL1248140 | 0.90 | FGFR4 (0.87) | FGFR4RETKDRFGFR1PDGFRB | |
| SCHEMBL30083661 | 0.89 | FGFR4 (0.86) | FGFR4RETKDRFGFR1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508313-B2 | Quinoline derivative-containing pharmaceutical composition | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-12-30 | — | — | US | claimed |
| EP-3957329-B1 | COMPOSITION COMPRISING THE COMBINATION OF SOTAGLIFLOZIN AS THE SODIUM/GLUCOSE CO-TRANSPORTER 1 INHIBITOR (SGLT1) AND A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 INHIBITOR (VEGFR2) FOR USE IN TREATING CANCER | NEWISH TECH BEIJING CO LTD (CN) | 2025-11-19 | — | — | EP | claimed |
| EP-3384901-B1 | PHARMACEUTICAL COMPOSITION COMPRISING LENVATINIB MESYLATE | SYNTHON BV (NL) | 2024-08-14 | — | — | EP | claimed |
| EP-3861347-B1 | BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND EVEROLIMUS | EISAI R&D MAN CO LTD (JP) | 2022-12-21 | — | — | EP | claimed |
| EP-3632436-B1 | PHARMACEUTICAL COMPOSITION COMPRISING LENVATINIB SALTS | SYNTHON BV (NL) | 2022-04-20 | — | — | EP | claimed |
| EP-3606511-B1 | PHARMACEUTICAL COMPOSITION COMPRISING LENVATINIB MESYLATE | SYNTHON BV (NL) | 2022-04-20 | — | — | EP | claimed |
| US-11236050-B2 | Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2022-02-01 | — | — | US | claimed |
| US-20210228722-A1 | QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-07-29 | — | — | US | claimed |
| US-11059787-B2 | Crystalline form of lenvatinib mesylate and methods thereof | SHENZHEN BOLAN PHARMACEUTICAL CO., LTD (CN) | 2021-07-13 | — | — | US | claimed |
| US-20210188778-A1 | NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-06-24 | — | — | US | claimed |
| EP-2567955-A2 | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these | Eisai R&D Management Co., Ltd. (JP) | 2013-03-13 | — | — | EP | claimed |
| EP-2468281-A1 | QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2012-06-27 | — | — | EP | claimed |
| US-20120077842-A1 | QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-03-29 | — | — | US | claimed |
| US-7612208-B2 | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | claimed |
| US-7550483-B2 | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | claimed |
| US-20080214557-A1 | METHOD FOR PREPARATION OF PHARMACEUTICAL COMPOSITION HAVING IMPROVED DISINTEGRATABILITY AND PHARMACEUTICAL COMPOSITION MANUFACTURED BY SAME METHOD | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | claimed |
| EP-1894918-A1 | AMORPHOUS SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMINOPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-03-05 | — | — | EP | claimed |
| US-20070078159-A1 | A CRYSTALLINE FORM OF THE SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMIN OPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR THE SOLVATE OF THE SALT AND A PROCESS FOR PREPARING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-04-05 | — | — | US | claimed |
| US-20070004773-A1 | Amorphous salt of 4-(3-chiloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | claimed |
| EP-1698623-A1 | CRYSTAL OF SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMINO-PHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR OF SOLVATE THEREOF AND PROCESSES FOR PRODUCING THESE | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508313-B2 | Quinoline derivative-containing pharmaceutical composition | CA2, KIT, CA7 | KDR 72/4885FLT1 84/4885FLT4 166/4885 |
| US-20120077842-A1 | QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RECQL, SFPQ | KDR 4161/4885FLT1 4225/4885FLT4 4259/4885 |
| US-11236050-B2 | Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof | UGT1A1, CYP4B1, CYP1B1 | KDR 4267/4885FLT1 2782/4885FLT4 3367/4885 |
| US-20210228722-A1 | QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RECQL, SFPQ | KDR 4175/4885FLT1 4240/4885FLT4 4271/4885 |
| US-20070004773-A1 | Amorphous salt of 4-(3-chiloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and process for preparing the same | CA7, CA4, CHIA | KDR 4339/4885FLT1 4790/4885FLT4 3881/4885 |
| US-20210188778-A1 | NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF | CYP4B1, UGT1A1, CYP3A4 | KDR 4133/4885FLT1 2933/4885FLT4 3160/4885 |
| US-20070078159-A1 | A CRYSTALLINE FORM OF THE SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMIN OPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR THE SOLVATE OF THE SALT AND A PROCESS FOR PREPARING THE SAME | AQP4, UACA, AQP3 | KDR 3394/4885FLT1 3838/4885FLT4 2668/4885 |
| US-11059787-B2 | Crystalline form of lenvatinib mesylate and methods thereof | ALK, CDK4, MAP1LC3C | KDR 81/4885FLT1 27/4885FLT4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.